BackAustralian Clinical Labs Limited Overview
Australian Clinical Labs Limited

Australian Clinical Labs Limited Return on Equity

Valuation check: ACL.AX's ROE is 37.55%, above the sector sector average of 11.3%.

Get informed when a big investor buys or sells

+ Follow

ROE

37.55%

Return on Equity

37.55%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Australian Clinical Labs Limited (ACL.AX) FAQ

Australian Clinical Labs Limited (ACL.AX) currently reports a ROE of 37.55%. That is above the sector sector average of 11.3%. Use the charts on this page to explore Australian Clinical Labs Limited's ROE history and peer comparisons.

Australian Clinical Labs Limited's ROE of 37.55% is higher than the its sector sector average of 11.3%. That is roughly 232.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Australian Clinical Labs Limited's current 37.55% should be judged against industry norms (sector average: 11.3%) and against ACL.AX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 37.55%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.3%. From there, open related valuation or income-statement pages for Australian Clinical Labs Limited, and consider following ACL.AX for alerts when major investors trade the stock.

Questions & Answers